Prospective Evaluation of Two iStent® Trabecular Stents, One iStent Supra® Suprachoroidal Stent, and Postoperative Prostaglandin in Refractory Glaucoma: 4-year Outcomes
Open Access
- 23 February 2018
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 35 (3) , 395-407
Abstract
Introduction This study evaluates long-term outcomes of two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin in eyes with refractory open angle glaucoma (OAG). Methods Prospective ongoing 5-year study of 80 eligible subjects (70 with 4-year follow-up) with OAG and IOP ≥ 18 mmHg after prior trabeculectomy and while taking 1–3 glaucoma medications. Subjects received two iStent® trabecular micro-bypass stents, one iStent Supra® suprachoroidal stent, and postoperative travoprost. Postoperative IOP was measured with medication and annually following medication washouts. Performance was measured by the proportion of eyes with ≥ 20% IOP reduction on one medication (the protocol-specified prostaglandin) versus preoperative medicated IOP (primary outcome); and the proportion of eyes with postoperative IOP ≤ 15 and ≤ 18 mmHg on one medication (secondary outcome). Additional clinical and safety data included medications, visual field, pachymetry, gonioscopy, adverse events, visual acuity, and slit-lamp and fundus examinations. Results Preoperatively, mean medicated IOP was 22.0 ± 3.1 mmHg on 1.2 ± 0.4 medications, and mean unmedicated IOP was 26.4 ± 2.4 mmHg. Postoperatively, among eyes without later cataract surgery, mean medicated IOP at all visits through 48 months was ≤ 13.7 mmHg (≥ 37% reduction), and annual unmedicated IOP was ≤ 18.4 mmHg (reductions of ≥ 30% vs. preoperative unmedicated IOP and ≥ 16% vs. preoperative medicated IOP). At all postoperative visits among eyes without additional surgery or medication, ≥ 91% of eyes had ≥ 20% IOP reduction on one medication versus preoperative medicated IOP. At month 48, 97 and 98% of eyes achieved IOP ≤ 15 and ≤ 18 mmHg, respectively, on one medication. Six eyes required additional medication, no eyes required additional glaucoma surgery, and safety measurements were favorable throughout follow-up. Conclusion IOP control was achieved safely with two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin. This microinvasive, ab interno approach introduces a possible new treatment option for refractory disease. Trial Registration NCT01456390. Funding Glaukos Corporation.Keywords
Funding Information
- Glaukos Corporation
This publication has 44 references indexed in Scilit:
- Outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic patient populationClinical Ophthalmology, 2016
- iStent inject in phakic open angle glaucomaGraefe's Archive for Clinical and Experimental Ophthalmology, 2015
- Latanoprost in the treatment of glaucomaClinical Ophthalmology, 2014
- Implantation of 2 trabecular microbypass stents in a patient with primary open-angle glaucoma refractory to previous glaucoma-filtering surgeriesJournal of Cataract & Refractive Surgery, 2014
- Efficacy and Safety of Trabeculectomy vs Nonpenetrating Surgical ProceduresJAMA Ophthalmology, 2013
- Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucomaJournal of Cataract & Refractive Surgery, 2010
- Late-onset bleb infections: Prevalence and risk factorsCanadian Journal of Ophthalmology, 2009
- Meta-analysis of 24-Hour Intraocular Pressure Studies Evaluating the Efficacy of Glaucoma MedicinesOphthalmology, 2008
- Trabeculectomy With Mitomycin C in Pseudophakic Patients With Open-angle Glaucoma: Outcomes and Risk Factors For FailureAmerican Journal of Ophthalmology, 2006
- Early manifest glaucoma trialOphthalmology, 1999